All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch

Dual Pricing Strategy Addresses Unique US Payer Priorities

 
• By Mandy Jackson

The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.  

Close-up Of man using Binoculars
Many are watching the Amjevita launch to see what it portends for uptake of other Humira biosimilars • Source: Shutterstock

More from Drug Pricing

More from Scrip